Medical News Today

How subcutaneous immunotherapy injections work for treating cancer

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...
Targeted Oncology

FDA Extends Review of Subcutaneous Isatuximab for Multiple Myeloma

The FDA review of the biologics license application includes data on SC isatuximab as both manual injection and via an ...
The American Journal of Managed Care

FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed noninferiority ...
CURE

Patient Experience Transitioning to Subcutaneous Therapy in Advanced Melanoma

Switching from IV to subcutaneous injection eases hard vein access, cuts clinic time, and boosts comfort with faster ...
The American Journal of Managed Care

First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA

Concizumab-mtci (Alhemo) is approved for hemophilia A or B with inhibitors, offering a subcutaneous alternative to intravenous treatments. The phase 3 explorer7 trial demonstrated an 86% reduction in ...
Nasdaq

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial ...
Healio

FDA approves Leqembi at-home subcutaneous injection in early Alzheimer’s

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...